163 related articles for article (PubMed ID: 24108562)
1. Assessment of liver tumor response to therapy: role of quantitative imaging.
Gonzalez-Guindalini FD; Botelho MP; Harmath CB; Sandrasegaran K; Miller FH; Salem R; Yaghmai V
Radiographics; 2013 Oct; 33(6):1781-800. PubMed ID: 24108562
[TBL] [Abstract][Full Text] [Related]
2. Assessing Imaging Response to Therapy.
Minocha J; Lewandowski RJ
Radiol Clin North Am; 2015 Sep; 53(5):1077-88. PubMed ID: 26321455
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
[TBL] [Abstract][Full Text] [Related]
4. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
5. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
6. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
7. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
Yaghmai V; Besa C; Kim E; Gatlin JL; Siddiqui NA; Taouli B
AJR Am J Roentgenol; 2013 Jul; 201(1):80-96. PubMed ID: 23789661
[TBL] [Abstract][Full Text] [Related]
8. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
Kim MN; Kim BK; Han KH; Kim SU
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor response on MR imaging after locoregional therapy.
Vossen JA; Buijs M; Kamel IR
Tech Vasc Interv Radiol; 2006 Sep; 9(3):125-32. PubMed ID: 17561215
[TBL] [Abstract][Full Text] [Related]
10. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
[TBL] [Abstract][Full Text] [Related]
11. Functional MR imaging as a new paradigm for image guidance.
Assumpcao L; Choti M; Pawlik TM; Gecshwind JF; Kamel IR
Abdom Imaging; 2009 Nov; 34(6):675-85. PubMed ID: 19048335
[TBL] [Abstract][Full Text] [Related]
12. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
13. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
14. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.
Yaghmai V; Miller FH; Rezai P; Benson AB; Salem R
AJR Am J Roentgenol; 2011 Jul; 197(1):18-27. PubMed ID: 21701006
[TBL] [Abstract][Full Text] [Related]
15. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
[TBL] [Abstract][Full Text] [Related]
16. Assessment of treatment response in hepatocellular carcinoma: a review of the literature.
Maida M; Cabibbo G; Brancatelli G; Genco C; Alessi N; Genova C; Romano P; Raineri M; Giarratano A; Midiri M; Cammà C
Future Oncol; 2013 Jun; 9(6):845-54. PubMed ID: 23718305
[TBL] [Abstract][Full Text] [Related]
17. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
[TBL] [Abstract][Full Text] [Related]
18. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
Chalian H; Töre HG; Horowitz JM; Salem R; Miller FH; Yaghmai V
Radiographics; 2011; 31(7):2093-105. PubMed ID: 22084190
[TBL] [Abstract][Full Text] [Related]
19. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
Riaz A; Memon K; Miller FH; Nikolaidis P; Kulik LM; Lewandowski RJ; Ryu RK; Sato KT; Gates VL; Mulcahy MF; Baker T; Wang E; Gupta R; Nayar R; Benson AB; Abecassis M; Omary R; Salem R
J Hepatol; 2011 Apr; 54(4):695-704. PubMed ID: 21147504
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II multicenter study of transarterial chemoembolization with a cisplatin fine powder and porous gelatin particles for unresectable hepatocellular carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401.
Osuga K; Arai Y; Anai H; Takeuchi Y; Aramaki T; Sugihara E; Yamamoto T; Inaba Y; Ganaha F; Seki H; Sadaoka S; Sato M; Kobayashi T; Kodama Y; Inoh S; Yamakado K
J Vasc Interv Radiol; 2012 Oct; 23(10):1278-85. PubMed ID: 22922041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
